ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending December 31, 2024: 63.05%

ImmunityBio, Inc. Return on Equity (ROE) is 63.05% for the Trailing 12 Months (TTM) ending December 31, 2024, a -44.66% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending December 31, 2023 was 113.93%, a 11.39% change year over year.
  • ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending December 31, 2022 was 102.28%, a -42.90% change year over year.
  • ImmunityBio, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending December 31, 2021 was 179.13%.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share